David G. Gaiero - 17 Jun 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc.

Role
Vice President, Finance
Signature
By: /s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jun 2021
Net transactions value
$0
Form type
3
Filing time
17 Jun 2021, 21:19:39 UTC
Next filing
07 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CYT Stock Option (Right to Buy) 17 Jun 2021 Common Stock 77,739 $1.67 Direct F1
holding CYT Stock Option (Right to Buy) 17 Jun 2021 Common Stock 29,016 $7.09 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% of the underlying shares of common stock on December 7, 2021, the first anniversary of the vesting commencement date, and 1/48th of the underlying shares thereafter on each subsequent monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
F2 The option vests as to 1/3rd of the underlying shares of common stock on February 5, 2022, the first anniversary of the of the vesting commencement date, and at a rate of 1/36th of the underlying shares of common stock at the end of each subsequent monthly anniversary of the vesting commencement date until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney